Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Equity Average (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Equity Average for 9 consecutive years, with $582.1 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 24.07% year-over-year to $582.1 million; the TTM value through Mar 2026 reached $582.1 million, down 24.07%, while the annual FY2025 figure was $701.5 million, 20.54% up from the prior year.
  • Equity Average hit $582.1 million in Q1 2026 for Bicycle Therapeutics, down from $614.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $852.4 million in Q3 2024 and bottomed at $231.6 million in Q2 2023.
  • Average Equity Average over 5 years is $493.8 million, with a median of $393.5 million recorded in 2023.
  • Year-over-year, Equity Average skyrocketed 184.79% in 2022 and then decreased 27.8% in 2023.
  • Bicycle Therapeutics' Equity Average stood at $280.1 million in 2022, then skyrocketed by 40.46% to $393.5 million in 2023, then soared by 106.38% to $812.0 million in 2024, then dropped by 24.36% to $614.2 million in 2025, then dropped by 5.22% to $582.1 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $582.1 million, $614.2 million, and $643.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.